Welab has signed an Agreement with the consortium IMI-Paincare, through the partner Consultech GmbH

IMI-Paincare is the biggest European consortium in the pain field, including some of the more relevant research centers and pharmaceutical companies working in pain research (Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No [77750]; https://www.imi-paincare.eu/PROJECT/).

The project is based on 3 sub-projects, PROMPT (focused on Patient Reported Out-come Measures), BIOPAIN (focused on back-translation of human pain biomarkers), and TRiPP (focused on improving animal models of endometriosis and bladder pain syndrome). Welab participates in two of them, providing its capacities and expertise in DMPK, and in vivo pharmacology.

The project started in 2018 and it will end in March 2023.